Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the UK

被引：0
|
作者：
Aballea, S.
Chancellor, J. V. M.
Raikou, M.
Drummond, M. F.
Jourdan, S.
Carita, P.
Bridgewater, J.
Boler, A.
机构：
[1] Innovus Res UK Ltd, High Wycombe, Bucks, England
[2] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England
[3] London Sch Econ, London, England
[4] Sanofi Aventis R&D, Global Hlth Outcomes, Bagneux, France
[5] UCL Royal Free & Univ Coll, Sch Med, London, England
[6] Heron Evidence Dev, Letchworth Garden City, England
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：178 / 178
页数：1
相关论文
共 50 条
  • [11] COST COMPARISON: CAPECITABINE plus OXALIPLATIN (XELOX) VS 5-FU/LV plus OXALIPLATIN (FOLFOX4) IN THE ADJUVANT TREATMENT OF PATIENTS WITH COLON CANCER (ACC)
    Winterhalder, R.
    Delmore, G.
    Hardegger, T.
    Urspruch, A.
    Hieke, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 201 - 202
  • [12] Stage II patients in the "MOSAIC" trial evaluating Oxaliplatin/5FU/LV as adjuvant treatment of colon cancer: a subpopulation analysis
    Hickish, Tamas
    Boni, Corrado
    Navarro, Matilde
    Tabernero, Josep
    Bonetti, Andrea
    Clingan, Philip
    Figer, Arie
    Andre, Thierry
    de Gramont, Aimery
    ANNALS OF ONCOLOGY, 2004, 15 : 76 - 76
  • [13] Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers
    Soni, Amy
    Aspinall, Sherrie L.
    Zhao, Xinhua
    Good, Chester B.
    Cunningham, Francesca E.
    Chatta, Gurkamal
    Passero, Vida
    Smith, Kenneth J.
    ONCOLOGY RESEARCH, 2015, 22 (5-6) : 311 - 319
  • [14] Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer
    Cappel, WHDN
    Meulenbeld, HJ
    Kleibeuker, JH
    Nagengast, FM
    Menko, FH
    Griffioen, G
    Cats, A
    Morreau, H
    Gelderblom, H
    Vasen, HFA
    INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (03) : 468 - 471
  • [15] COST-EFFECTIVENESS OF OXALIPLATIN AND IRINOTECAN BASED COMBINATION THERAPY COMPARED WITH 5FU/LV FOR THE TREATMENT OF US ELDERLY ADVANCED COLON CANCER PATIENTS
    Hsiao, F. Y.
    Mullins, C. D.
    Onukwugha, E.
    Pandya, N. B.
    Seal, B.
    Hanna, N.
    VALUE IN HEALTH, 2010, 13 (03) : A34 - A35
  • [16] Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer:: Efficacy results with a median follow-up of 4 years.
    de Gramont, A
    Boni, C
    Navarro, M
    Tabernero, J
    Hickish, T
    Topham, C
    Bonetti, A
    Clingan, P
    Marceau-Suissa, J
    Lorenzato, C
    André, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 246S - 246S
  • [17] Two Pan-European trials in adjuvant colon cancer (PETACC 1&2):: The efficacy of Tomudex® compared to bolus 5-Fluorouracil/leucovorin (5-FU/LV); and high dose infusional 5-FU compared to bolus 5-FU/LV, in patients with stage III colon cancer
    Wils, J
    ANNALS OF ONCOLOGY, 1998, 9 : 45 - 45
  • [18] COST EFFECTIVENESS OF CAPECITABINE IN COMBINATION WITH OXALIPLATIN (XELOX) COMPARED TO FOLFOX (5-FU, LV, OXALIPLATIN) FOR THE TREATMENT OF METASTATIC CARCINOMA OF THE COLON OR RECTUM (CRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
    Millar, D. R.
    Ducournau, P.
    McDonald, A.
    VALUE IN HEALTH, 2008, 11 (06) : A344 - A344
  • [19] A prospective randomized phase III trial of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with stage II colon cancer
    Schippinger, W.
    Samonigg, H.
    Greil, R.
    Tschmelitsch, J.
    Steger, G.
    Jakesz, R.
    Gnant, M.
    Hofbauer, F.
    Rabl, H.
    Thaler, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [20] Cost-effectiveness of oxaliplatin/5FU/LV (FOLFOX) vs. irinotecan/5FU/LV (IFL) as first-line treatment of metastatic colorectal cancer
    Aballea, S.
    Najib, M.
    Cure, S.
    O'Neil, B.
    ANNALS OF ONCOLOGY, 2006, 17 : 66 - 66
12345